Equity Overview
Price & Market Data
Price: $0.356
Daily Change: +$0.012 / 3.37%
Range: $0.356 - $0.356
Market Cap: $78,435,088
Volume: 300
Performance Metrics
1 Week: -3.29%
1 Month: -32.95%
3 Months: -57.94%
6 Months: -58.07%
1 Year: -54.51%
YTD: -48.09%
Company Details
Employees: 115
Sector: Health technology
Industry: Biotechnology
Country: United States
Details
Vaxart, Inc., a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its vector-adjuvant-antigen standardized technology proprietary oral vaccine platform in the United States. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions. It has a license agreement with Altesa Biosciences, Inc. to develop and commercialize Vapendavir, a capsid-binding broad-spectrum antiviral. Vaxart, Inc. is headquartered in South San Francisco, California.